# OnCo record her2-testing-in-biliary-cancer (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/her2-testing-in-biliary-cancer/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "her2-testing-in-biliary-cancer" ;
  schema:name "HER2 testing in biliary tract cancer (IHC, ISH and NGS)"@en ;
  schema:alternateName "HER2 scoring in biliary cancer"@en, "HERIZON-BTC-01 HER2 criteria"@en, "HER2 IHC versus ISH in cholangiocarcinoma"@en, "ERBB2 amplification by NGS"@en ;
  schema:description "Bile duct and gallbladder tumours are scored for HER2 with the stomach cancer rules, not the breast ones, and a strong stain (3+) is enough for zanidatamab. A borderline stain (2+) needs a gene-copy test, and a sequencing panel can find both the amplification and the rarer point mutations that a stain misses."@en ;
  schema:url <https://onco.cc/terms/her2-testing-in-biliary-cancer/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/s1470-2045(23)00242-5>, <https://doi.org/10.1016/j.humpath.2026.106234>, <https://doi.org/10.1016/j.humpath.2020.08.006>, <https://doi.org/10.1200/go.24.00090> ;
  onco:related <https://onco.cc/biomarkers/her2-ihc-3-plus/>, <https://onco.cc/biomarkers/her2-ihc-2-plus/>, <https://onco.cc/biomarkers/her2-ish-amplified/>, <https://onco.cc/biomarkers/her2-mutation/> ;
  onco:cancers <https://onco.cc/cancers/gallbladder/>, <https://onco.cc/cancers/biliary-tract-cancer/>, <https://onco.cc/cancers/cholangiocarcinoma/> ;
  onco:technologies <https://onco.cc/technologies/cgp/>, <https://onco.cc/technologies/liquid-biopsy/> ;
  onco:targets <https://onco.cc/targets/her2/> ;
  onco:drugs <https://onco.cc/drugs/zanidatamab/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/drugs/her2-testing-assays/>, <https://onco.cc/drugs/foundationone-cdx/>, <https://onco.cc/drugs/guardant360-cdx/> ;
  onco:terms <https://onco.cc/terms/ihc/>, <https://onco.cc/terms/fish/>, <https://onco.cc/terms/ngs/>, <https://onco.cc/terms/gene-amplification/>, <https://onco.cc/terms/her2-positive/>, <https://onco.cc/terms/ctdna/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-harding-lancet-oncol/>, <https://onco.cc/key-papers/paper-angerilli-her2-ihc-cish-biliary-hum-pathol-2026/>, <https://onco.cc/key-papers/paper-hiraoka-her2-status-biliary-hum-pathol-2020/>, <https://onco.cc/key-papers/paper-mondaca-erbb2-gallbladder-us-chile-jco-go-2024/>, <https://onco.cc/key-papers/paper-suryavanshi-indian-gallbladder-genomics-jco-go-2025/>, <https://onco.cc/key-papers/paper-mody-biliary-ctdna-profiling-jco-po-2019/> .